XML 71 R60.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue and Accounts Receivable Credit Concentration - Additional Information (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2024
USD ($)
Test
Dec. 31, 2023
USD ($)
Disaggregation Of Revenue [Line Items]    
Sources of revenue, description We derive our revenue from two sources: (i) Lung Diagnostic Testing, providing lung diagnostic testing services for healthcare providers associated with our five blood-based tests and (ii) Development Services, providing diagnostic testing services to biopharmaceutical, life sciences, and diagnostic companies.  
Revenue recognized $ 900  
Deferred revenue $ 678 $ 324
Number of blood based lung cancer test | Test 5  
Revenue | Minimum | Customer Concentration Risk | Medicare    
Disaggregation Of Revenue [Line Items]    
Concentration risk, percentage 39.00% 43.00%
Other Long-term Liabilities    
Disaggregation Of Revenue [Line Items]    
Non-current deferred revenue $ 200 $ 300
Up Front Cash Payments    
Disaggregation Of Revenue [Line Items]    
Deferred revenue $ 1,300